O'Day Daniel Patrick 4

What Happened Daniel O'Day, Chairman & CEO (and Director) of Gilead Sciences (GILD), sold a total of 10,000 shares in two open‑market transactions on January 28, 2026. He disposed of 5,032 shares at $139.54 for $702,186 and 4,968 shares at $140.24 for $696,725, for an aggregate proceeds of about $1,398,911. These were sales (not purchases), which are often routine dispositions.

Key Details

• Transaction dates: 2026-01-28 (filed on 2026-01-29)
• Reported trades:
  • 5,032 shares sold @ $139.54 = $702,186
  • 4,968 shares sold @ $140.24 = $696,725
• Aggregate proceeds: ≈ $1.40 million
• Shares owned after transaction: not specified in the provided filing excerpt
• Footnotes:
  • F1: Transactions were executed under a Rule 10b5‑1 trading plan adopted February 28, 2025 (pre‑arranged plan).
  • F2/F3: Reported sale price ranges span $138.99–$139.97 and $140.00–$140.57; detailed per‑price share counts will be provided to the SEC, issuer, or shareholders upon request.
• Filing timeliness: transaction dated 1/28/2026 and Form 4 filed 1/29/2026 (no late‑filing indication in the provided data).

Context Sales under a 10b5‑1 plan are pre‑scheduled trades that allow insiders to sell shares without suggesting a change in their view of the company; they are common and do not necessarily reflect current sentiment. For retail investors, purchases usually carry more informational weight than routine sales, but noting insider activity and timing can still be useful when evaluating positions. If you need the post‑sale holdings or the exact breakdown of prices, that information can be requested from the SEC or issuer as noted in the footnotes.